IL139244A - שיטה להגדלת תאי cd34 באוכלוסיית תאים - Google Patents
שיטה להגדלת תאי cd34 באוכלוסיית תאיםInfo
- Publication number
- IL139244A IL139244A IL139244A IL13924496A IL139244A IL 139244 A IL139244 A IL 139244A IL 139244 A IL139244 A IL 139244A IL 13924496 A IL13924496 A IL 13924496A IL 139244 A IL139244 A IL 139244A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- cell
- receptor
- antigen
- hla
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 90
- 210000004027 cell Anatomy 0.000 claims description 495
- 239000000427 antigen Substances 0.000 claims description 127
- 102000036639 antigens Human genes 0.000 claims description 127
- 108091007433 antigens Proteins 0.000 claims description 127
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 69
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 58
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 58
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 51
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 51
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 48
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 28
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 28
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 16
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 16
- 210000001616 monocyte Anatomy 0.000 claims description 16
- 210000003714 granulocyte Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000001332 colony forming effect Effects 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 7
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 102000043131 MHC class II family Human genes 0.000 claims description 5
- 108091054438 MHC class II family Proteins 0.000 claims description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 210000003651 basophil Anatomy 0.000 claims description 5
- 230000008512 biological response Effects 0.000 claims description 5
- 210000003979 eosinophil Anatomy 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 5
- 210000003593 megakaryocyte Anatomy 0.000 claims description 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 2
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 2
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims description 2
- 210000004524 haematopoietic cell Anatomy 0.000 claims description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 1
- 102000015789 HLA-DP Antigens Human genes 0.000 claims 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 156
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 156
- 210000004369 blood Anatomy 0.000 description 135
- 239000008280 blood Substances 0.000 description 134
- 238000011282 treatment Methods 0.000 description 121
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 81
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 81
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 64
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 50
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 50
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 48
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 48
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 36
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 230000008569 process Effects 0.000 description 26
- 210000004698 lymphocyte Anatomy 0.000 description 25
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 23
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 23
- 230000007423 decrease Effects 0.000 description 23
- 210000000130 stem cell Anatomy 0.000 description 20
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 17
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 15
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 15
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 15
- 102000000844 Cell Surface Receptors Human genes 0.000 description 13
- 108010001857 Cell Surface Receptors Proteins 0.000 description 13
- 238000013394 immunophenotyping Methods 0.000 description 13
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 10
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 9
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 8
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 102100022749 Aminopeptidase N Human genes 0.000 description 6
- 102000013925 CD34 antigen Human genes 0.000 description 6
- 108050003733 CD34 antigen Proteins 0.000 description 6
- 108010041397 CD4 Antigens Proteins 0.000 description 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 102100032768 Complement receptor type 2 Human genes 0.000 description 5
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000010910 CD28 Antigens Human genes 0.000 description 4
- 108010062433 CD28 Antigens Proteins 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 4
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 4
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 4
- 102000003729 Neprilysin Human genes 0.000 description 4
- 108090000028 Neprilysin Proteins 0.000 description 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000004730 hepatocarcinogenesis Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 101150076401 16 gene Proteins 0.000 description 1
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000008162 B cell deficiency Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108010003639 CD56 Antigen Proteins 0.000 description 1
- 102000004652 CD56 Antigen Human genes 0.000 description 1
- 108010001017 CD71 antigen Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 238000006711 Chan reduction reaction Methods 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 208000007924 IgA Deficiency Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 101710177649 Low affinity immunoglobulin gamma Fc region receptor III Proteins 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000003104 cytoplasmic structure Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9502022.8A GB9502022D0 (en) | 1995-02-02 | 1995-02-02 | A method for preparing lymphohaematopoietic progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL139244A true IL139244A (he) | 2006-10-05 |
Family
ID=10768971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL139244A IL139244A (he) | 1995-02-02 | 1996-01-31 | שיטה להגדלת תאי cd34 באוכלוסיית תאים |
| IL11699496A IL116994A (en) | 1995-02-02 | 1996-01-31 | Method of preparing an undifferentiated cell |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11699496A IL116994A (en) | 1995-02-02 | 1996-01-31 | Method of preparing an undifferentiated cell |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6090625A (he) |
| EP (1) | EP0807166B1 (he) |
| JP (4) | JPH10513053A (he) |
| KR (1) | KR100630591B1 (he) |
| CN (1) | CN1289660C (he) |
| AP (1) | AP693A (he) |
| AT (1) | ATE396253T1 (he) |
| AU (1) | AU4545196A (he) |
| BR (1) | BR9606866A (he) |
| CA (1) | CA2211147C (he) |
| CY (1) | CY2206B1 (he) |
| DE (1) | DE69637534D1 (he) |
| DK (1) | DK0807166T3 (he) |
| ES (1) | ES2308774T3 (he) |
| GB (1) | GB9502022D0 (he) |
| HK (1) | HK1017710A1 (he) |
| IL (2) | IL139244A (he) |
| NZ (1) | NZ300650A (he) |
| PT (1) | PT807166E (he) |
| RU (2) | RU2177996C2 (he) |
| SI (1) | SI0807166T1 (he) |
| WO (1) | WO1996023870A1 (he) |
| ZA (1) | ZA96727B (he) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9068164B1 (en) | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
| GB9502022D0 (en) * | 1995-02-02 | 1995-03-22 | Abuljadayel Ilham M S | A method for preparing lymphohaematopoietic progenitor cells |
| US8609412B2 (en) * | 1999-08-05 | 2013-12-17 | Regents Of The University Of Minnesota | Mapc generation of lung tissue |
| US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
| WO2005056026A1 (en) | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US8075881B2 (en) * | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| DK1226233T3 (da) * | 1999-08-05 | 2011-10-03 | Abt Holding Co | Multipotente voksne stamceller og fremgangsmåder til isolering heraf |
| CN101538551A (zh) * | 2000-05-10 | 2009-09-23 | 特里施泰姆贸易(塞浦路斯)有限公司 | 一种设备 |
| NL1017973C2 (nl) * | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
| EP1367899A4 (en) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS |
| DE10144326B4 (de) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Verfahren und System zur Überwachung eines Reifenluftdrucks |
| TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| EP1644484B1 (en) * | 2003-07-11 | 2008-09-17 | Blasticon Biotechnologische Forschung GmbH | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations |
| DE10231655A1 (de) * | 2002-07-12 | 2004-02-26 | Blasticon Biotechnologische Forschung Gmbh | Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
| AU2003298016A1 (en) | 2002-11-27 | 2004-06-23 | Regents Of The University Of Minnesota | Homologous recombination in multipotent adult progenitor cells |
| RU2363491C2 (ru) * | 2003-08-12 | 2009-08-10 | Тижени Н. В. | Применение хемокина cxcl6 в предотвращении или восстановлении хрящевых дефектов |
| WO2006047743A2 (en) * | 2004-10-26 | 2006-05-04 | Regents Of The University Of Minnesota | Swine multipotent adult progenitor cells |
| CA2597757C (en) * | 2005-02-10 | 2016-06-28 | Regents Of The University Of Minnesota | Vascular/lymphatic endothelial cells |
| AU2005331534B2 (en) * | 2005-05-05 | 2011-12-08 | Regents Of The University Of Minnesota | Use of MAPC or progeny therefrom to populate lymphohematopoietic tissues |
| EP1877540A1 (en) * | 2005-05-05 | 2008-01-16 | Regents Of The University Of Minnesota | Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells |
| WO2007117262A2 (en) * | 2005-07-29 | 2007-10-18 | Athersys, Inc. | Culture of non-embryonic cells at high cell density |
| NZ567082A (en) * | 2005-10-14 | 2012-08-31 | Univ Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
| EP2087101A2 (en) * | 2006-11-24 | 2009-08-12 | Regents of the University of Minnesota | Endodermal progenitor cells |
| EP2245141B1 (en) * | 2008-01-18 | 2018-03-14 | Regents of the University of Minnesota | Stem cell aggregates and methods for making and using |
| US9057051B2 (en) | 2008-10-31 | 2015-06-16 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells |
| KR101811235B1 (ko) | 2009-06-05 | 2017-12-21 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | Ｔ 세포 및 조혈 세포의 재프로그래밍 |
| SG10201404280XA (en) * | 2009-07-21 | 2014-10-30 | Abt Holding Co | Use of stem cells to reduce leukocyte extravasation |
| EP2456860B1 (en) * | 2009-07-21 | 2018-09-05 | ABT Holding Company | Use of stem cells to reduce leukocyte extravasation |
| RU2661107C1 (ru) * | 2009-09-15 | 2018-07-11 | Зэ Юниверсити оф Токио | Новый способ получения дифференцированных клеток |
| RU2635317C2 (ru) * | 2009-10-19 | 2017-11-10 | Тристем Трейдинг (Сайпрес) Лимитед | Лечение с применением перепрограммированных зрелых и дифференцированных клеток |
| US20110206647A1 (en) * | 2010-02-25 | 2011-08-25 | Abt Holding Company | Modulation of Angiogenesis |
| WO2011106476A1 (en) * | 2010-02-25 | 2011-09-01 | Abt Holding Company | Modulation of microglia activation |
| US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
| CA2798895A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy |
| US9090878B2 (en) | 2010-06-17 | 2015-07-28 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
| SG188280A1 (en) | 2010-08-24 | 2013-04-30 | Univ Minnesota | Non-static suspension culture of cell aggregates |
| SG10201809901SA (en) * | 2012-04-24 | 2018-12-28 | Vcell Therapeutics Inc | Generating Pluripotent Cells De Novo |
| RU2497947C1 (ru) * | 2012-08-15 | 2013-11-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства зравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития России) | Способ модификации моноцитов периферической крови для повышения их паракринной активности при аутологической трансплантации |
| PT2983680T (pt) | 2013-04-12 | 2020-10-29 | Abt Holding Co | Melhoria de órgãos para transplante |
| JP6918003B2 (ja) | 2016-01-21 | 2021-08-11 | エイビーティー ホールディング カンパニー | 創傷治癒のための幹細胞 |
| JP2017008049A (ja) * | 2016-07-04 | 2017-01-12 | トライステム・トレイディング・（キプロス）・リミテッドＴｒｉＳｔｅｍ Ｔｒａｄｉｎｇ （Ｃｙｐｒｕｓ） Ｌｉｍｉｔｅｄ | 再プログラム化成熟成体細胞を用いる治療 |
| US20220125852A1 (en) * | 2020-10-27 | 2022-04-28 | Therapeutic Solutions International, Inc. | Protection and regeneration of neurological function by using stem cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US6194376B1 (en) * | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| CA2121370C (en) * | 1991-11-22 | 2003-03-18 | David H. Sachs | Specific tolerance in transplantation |
| WO1993025216A1 (en) * | 1992-06-08 | 1993-12-23 | Becton, Dickinson And Company | Human primitive stem cells |
| DE4240635C2 (de) * | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| GB9502022D0 (en) * | 1995-02-02 | 1995-03-22 | Abuljadayel Ilham M S | A method for preparing lymphohaematopoietic progenitor cells |
| US5877299A (en) * | 1995-06-16 | 1999-03-02 | Stemcell Technologies Inc. | Methods for preparing enriched human hematopoietic cell preparations |
| US5843633A (en) * | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
| US6227202B1 (en) * | 1996-09-03 | 2001-05-08 | Maulana Azad Medical College | Method of organogenesis and tissue regeneration/repair using surgical techniques |
| US6468794B1 (en) * | 1999-02-12 | 2002-10-22 | Stemcells, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
-
1995
- 1995-02-02 GB GBGB9502022.8A patent/GB9502022D0/en active Pending
-
1996
- 1996-01-31 AP APAP/P/1997/001031A patent/AP693A/en active
- 1996-01-31 ES ES96901432T patent/ES2308774T3/es not_active Expired - Lifetime
- 1996-01-31 RU RU97114802/14A patent/RU2177996C2/ru active
- 1996-01-31 IL IL139244A patent/IL139244A/he not_active IP Right Cessation
- 1996-01-31 DK DK96901432T patent/DK0807166T3/da active
- 1996-01-31 AT AT96901432T patent/ATE396253T1/de active
- 1996-01-31 SI SI9630761T patent/SI0807166T1/sl unknown
- 1996-01-31 BR BR9606866A patent/BR9606866A/pt not_active Application Discontinuation
- 1996-01-31 JP JP8523345A patent/JPH10513053A/ja active Pending
- 1996-01-31 NZ NZ300650A patent/NZ300650A/en not_active IP Right Cessation
- 1996-01-31 WO PCT/GB1996/000208 patent/WO1996023870A1/en active IP Right Grant
- 1996-01-31 RU RU2000130595/14A patent/RU2215539C2/ru active IP Right Revival
- 1996-01-31 PT PT96901432T patent/PT807166E/pt unknown
- 1996-01-31 IL IL11699496A patent/IL116994A/xx not_active IP Right Cessation
- 1996-01-31 KR KR1019970705346A patent/KR100630591B1/ko active IP Right Grant
- 1996-01-31 DE DE69637534T patent/DE69637534D1/de not_active Expired - Lifetime
- 1996-01-31 AU AU45451/96A patent/AU4545196A/en not_active Abandoned
- 1996-01-31 CN CNB961930217A patent/CN1289660C/zh not_active Expired - Lifetime
- 1996-01-31 CA CA2211147A patent/CA2211147C/en not_active Expired - Lifetime
- 1996-01-31 US US08/594,164 patent/US6090625A/en not_active Expired - Lifetime
- 1996-01-31 ZA ZA96727A patent/ZA96727B/xx unknown
- 1996-01-31 EP EP96901432A patent/EP0807166B1/en not_active Expired - Lifetime
-
1998
- 1998-10-13 HK HK98111223A patent/HK1017710A1/xx not_active IP Right Cessation
-
2000
- 2000-03-09 US US09/521,700 patent/US20020076812A1/en not_active Abandoned
- 2000-12-21 CY CY0000061A patent/CY2206B1/xx unknown
-
2007
- 2007-07-12 JP JP2007183193A patent/JP2007259868A/ja active Pending
-
2008
- 2008-12-25 JP JP2008330347A patent/JP2009148266A/ja active Pending
-
2011
- 2011-02-23 US US13/033,093 patent/US20110143431A1/en not_active Abandoned
- 2011-10-05 JP JP2011220926A patent/JP2012040011A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2211147C (en) | A method of preparing an undifferentiated cell | |
| US7410773B2 (en) | Method of preparing an undifferentiated cell | |
| EP1366144B1 (en) | A device for preparing cells | |
| US7112440B2 (en) | Method of increasing the relative number of CD45 low cells in a cell population | |
| US7220412B2 (en) | Method of preparing an undifferentiated cell | |
| GB2297558A (en) | Conversion of a more committed cell into an undifferentiated cell | |
| AU744745B2 (en) | Medicament comprising undifferentiated cells | |
| AU751928B2 (en) | A method of preparing an undifferentiated cell | |
| IL133155A (en) | Method for producing a medicament comprising retrodifferentiated cells | |
| CA2395452A1 (en) | A method of preparing an undifferentiated cell | |
| AU7243100A (en) | A method of preparing an undifferentiated cell | |
| AU2005201200B2 (en) | A Method of Preparing an Undifferentiated Cell | |
| AU2006203449B2 (en) | A Device | |
| MXPA97005919A (en) | A method for preparing an indiferencial cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| EXP | Patent expired |